Traders Purchase Large Volume of AMAG Pharmaceuticals Call Options (AMAG)

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) was the target of unusually large options trading activity on Tuesday. Traders acquired 3,963 call options on the stock. This is an increase of 1,062% compared to the average daily volume of 341 call options.

Several analysts have weighed in on the stock. Jefferies Group reissued a “buy” rating and issued a $16.00 price target on shares of AMAG Pharmaceuticals in a research note on Sunday, November 5th. ValuEngine downgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Piper Jaffray Companies assumed coverage on shares of AMAG Pharmaceuticals in a research note on Monday, October 23rd. They issued a “neutral” rating and a $18.00 price target for the company. BidaskClub raised shares of AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 24th. Finally, B. Riley reissued a “hold” rating and issued a $16.00 price target on shares of AMAG Pharmaceuticals in a research note on Monday, January 29th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and two have given a buy rating to the company. AMAG Pharmaceuticals has an average rating of “Hold” and an average price target of $19.89.

Several hedge funds have recently added to or reduced their stakes in AMAG. Balter Liquid Alternatives LLC purchased a new position in shares of AMAG Pharmaceuticals in the fourth quarter valued at about $120,000. Teacher Retirement System of Texas purchased a new position in shares of AMAG Pharmaceuticals in the fourth quarter valued at about $162,000. Hartford Investment Management Co. purchased a new position in shares of AMAG Pharmaceuticals in the third quarter valued at about $186,000. Two Sigma Securities LLC purchased a new position in shares of AMAG Pharmaceuticals in the fourth quarter valued at about $187,000. Finally, 361 Capital LLC purchased a new position in shares of AMAG Pharmaceuticals in the third quarter valued at about $197,000.

AMAG Pharmaceuticals (NASDAQ:AMAG) traded up $0.20 during mid-day trading on Wednesday, hitting $13.90. 1,032,581 shares of the company’s stock were exchanged, compared to its average volume of 1,001,212. AMAG Pharmaceuticals has a 12-month low of $11.93 and a 12-month high of $25.20. The stock has a market capitalization of $488.74, a PE ratio of -2.29 and a beta of 0.79. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.48.

COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/02/14/traders-purchase-large-volume-of-amag-pharmaceuticals-call-options-amag.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply